Navigation Links
Siemens Completes Acquisition of Dade Behring
Date:11/6/2007

Complementing business of Siemens Medical Solutions Diagnostics

ERLANGEN, Germany, Nov. 6 /PRNewswire-FirstCall/ -- Siemens has successfully completed the acquisition of Dade Behring Holdings, Inc. The laboratory diagnostics company joins the existing business of Siemens Medical Solutions Diagnostics. As the market leader in the attractive and rapidly growing field of in vitro diagnostics, Siemens now can offer its customers a unique and comprehensive healthcare solutions' portfolio, which brings together the entire medical imaging, laboratory diagnostics and clinical information technology (IT) value chain under one roof.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

"The acquisition of Dade Behring, which holds a strong position in clinical chemistry, ideally complements our acquisitions of Diagnostic Products Corporation and Bayer Diagnostics," explained Erich R. Reinhardt, member of the Managing Board of Siemens AG and President and CEO of Siemens Medical Solutions. "The implementation of integrated IT and clinical solutions from Siemens will help improve workflow efficiency throughout the healthcare enterprise, from admissions and administration, to the laboratory and the radiology department. This will enable our customers to increase the quality of patient care while simultaneously reducing costs," Reinhardt added.

As the first and only global fully integrated diagnostics company, Siemens Medical Solutions is in a unique position to leverage trendsetting solutions across the entire healthcare continuum - from prevention to diagnosis, to therapy and care.

Siemens (Berlin and Munich) is a global powerhouse in electrical engineering and electronics. The company has around 475,000 employees (incl. discontinued operations) working to develop and manufacture products, design and install complex systems and projects, and tailor a wide range of services for individual requirements. Siemens provides innovative technologies and comprehensive know-how to benefit customers in over 190 countries. Founded more than 160 years ago, the company focuses on the areas of Information and Communications, Automation and Control, Power, Transportation, Medical, and Lighting. In fiscal 2006 (ended September 30), Siemens had sales of euro 87.3 billion and net income of euro 3.033 billion, according to U.S. GAAP. Further information is available on the Internet at: http://www.siemens.com

Siemens Medical Solutions of Siemens AG is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Acquisitions in the area of in-vitro diagnostics - such as Diagnostic Products Corporation Bayer Diagnostics and Dade Behring- mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of euro 8.23 billion, orders of euro 9.33 billion and group profit of euro 1.06 billion for fiscal 2006 (Sept. 30), according to U.S. GAAP. Further information can be found by visiting http://www.siemens.com/medical.

This document contains forward-looking statements and information - that is, statements related to future, not past, events. These statements may be identified by words as "expects," "looks forward to," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning. Such statements are based on our current expectations and certain assumptions, and are, therefore, subject to certain risks and uncertainties. A variety of factors, many of which are beyond Siemens' control, affect its operations, performance, business strategy and results and could cause the actual results, performance or achievements of Siemens worldwide to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. For us, particular uncertainties arise, among others, from: changes in general economic and business conditions (including margin developments in major business areas); the challenges of integrating major acquisitions and implementing joint ventures and other significant portfolio measures; changes in currency exchange rates and interest rates; introduction of competing products or technologies by other companies; lack of acceptance of new products or services by customers targeted by Siemens worldwide; changes in business strategy; the outcome of pending investigations and legal proceedings; our analysis of the potential impact of such matters on our financial statements; as well as various other factors. More detailed information about our risk factors is contained in Siemens' filings with the SEC, which are available on the Siemens website, http://www.siemens.com, and on the SEC's website, http://www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the relevant forward-looking statement as expected, anticipated, intended, planned, believed, sought, estimated or projected. Siemens does not intend or assume any obligation to update or revise these forward-looking statements in light of developments which differ from those anticipated.


'/>"/>
SOURCE Siemens Medical Solutions
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
2. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Carrington Completes $8 Million Financing
8. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
9. New Brunswick Scientific Completes Merger Transaction with Eppendorf
10. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
11. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... pleased to announce that Biohaven has issued today the ... Connecticut (PRWEB) Dec 9, 2016 - Biohaven ... today that the U.S. Food and Drug Administration ("FDA") ... its drug candidate BHV-0223, an orally dissolving tablet being ...
(Date:12/8/2016)... PITTSBURGH , Dec. 8, 2016  The Board ... (PLSG), Western Pennsylvania,s only ... in leadership. In accordance with the succession plan developed ... several years, effective today, James (Jim) F. Jordan ... Executive Officer, succeeding John W. Manzetti , who ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, San ... a banner year for team building events, new program offerings and company expansion. ... expanded earlier this year to include groups of over 30 people. Ever since, Lajollacooks4u ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... platforms, the business of innovation is taking over sports. On Thursday, December 15th ... explore how technology is disrupting the playing field at a Smart Talk session. ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):